Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics, Millipore

Premium
Bioinformatics has released a new research report entitled “Optimizing Synthetic RNAi: Perspectives from the Pharmaceutical and Biotech Industry.

The report states that “while the use of synthetic siRNA is still relatively new, the industrial market segment will continue strong growth over the near term,” the company said. “Among current industrial users of siRNA, an overall growth rate of 9 percent is projected for the next twelve months. In addition, about one-third of survey respondents indicate that they do not now conduct RNAi experiments but plan to do so in the upcoming months, implying further market growth potential.”
 

 
Millipore has recently introduced AdenoSilence shRNA-expression vectors.
 
According to the company, the vectors target the human druggable genome and include major protein classes amenable to small-molecule intervention such as kinases, GPCRs, ion channels, proteases, nuclear hormone receptors, secreted proteins, and receptors.
 
The vectors are available in three different sequence variants sold individually or as a kit containing all three.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.